Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Case Report: Treatment of systemic mastocytosis with sunitinib.

Molderings GJ, Afrin LB, Hertfelder HJ, Brettner S.

F1000Res. 2017 Dec 28;6:2182. doi: 10.12688/f1000research.13343.1. eCollection 2017.

2.

Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA.

Molderings GJ, Zienkiewicz T, Homann J, Menzen M, Afrin LB.

F1000Res. 2017 Oct 26;6:1889. doi: 10.12688/f1000research.12730.1. eCollection 2017.

3.

Response to: "In reply to: 'Mast Cell Disorders in Ehlers-Danlos Syndrome' (Jaime Vengoechea, Department of Human Genetics, Emory University)".

Seneviratne SL, Maitland A, Afrin LB.

Am J Med Genet A. 2018 Jan;176(1):251-252. doi: 10.1002/ajmg.a.38528. Epub 2017 Nov 21. No abstract available.

PMID:
29160015
4.

Successful targeted treatment of mast cell activation syndrome with tofacitinib.

Afrin LB, Fox RW, Zito SL, Choe L, Glover SC.

Eur J Haematol. 2017 Aug;99(2):190-193. doi: 10.1111/ejh.12893. Epub 2017 May 3.

PMID:
28382662
5.

Characterization of Mast Cell Activation Syndrome.

Afrin LB, Self S, Menk J, Lazarchick J.

Am J Med Sci. 2017 Mar;353(3):207-215. doi: 10.1016/j.amjms.2016.12.013. Epub 2016 Dec 16.

6.

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O.

Lancet. 2017 Feb 11;389(10069):612-620. doi: 10.1016/S0140-6736(16)31403-9. Epub 2017 Jan 7.

7.

The Good, The Bad, and The Ugly of the New Doctor-Patient-Computer Relationship of the 21st Century.

Afrin LB.

J S C Med Assoc. 2015 Jun;111(2):48-52, 54. No abstract available.

PMID:
27132331
8.

Pharmacological treatment options for mast cell activation disease.

Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL, Panse J, Butterfield J, Afrin LB.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Jul;389(7):671-94. doi: 10.1007/s00210-016-1247-1. Epub 2016 Apr 30. Review.

9.

A new era for an old cell: heightened appreciation of mast cell disease emerges.

Afrin LB.

Transl Res. 2016 Aug;174:1-4. doi: 10.1016/j.trsl.2016.03.003. Epub 2016 Mar 10. No abstract available.

PMID:
27016701
10.

Often seen, rarely recognized: mast cell activation disease--a guide to diagnosis and therapeutic options.

Afrin LB, Butterfield JH, Raithel M, Molderings GJ.

Ann Med. 2016;48(3):190-201. doi: 10.3109/07853890.2016.1161231. Epub 2016 Mar 25. Review.

PMID:
27012973
11.

Mast cell activation disease and the modern epidemic of chronic inflammatory disease.

Afrin LB.

Transl Res. 2016 Aug;174:33-59. doi: 10.1016/j.trsl.2016.01.003. Epub 2016 Jan 18. Review.

PMID:
26850903
12.

Mast Cell-Mediated Mechanisms of Nociception.

Aich A, Afrin LB, Gupta K.

Int J Mol Sci. 2015 Dec 4;16(12):29069-92. doi: 10.3390/ijms161226151. Review.

13.

Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases.

Afrin LB, Pöhlau D, Raithel M, Haenisch B, Dumoulin FL, Homann J, Mauer UM, Harzer S, Molderings GJ.

Brain Behav Immun. 2015 Nov;50:314-321. doi: 10.1016/j.bbi.2015.07.002. Epub 2015 Jul 8. Review.

PMID:
26162709
14.

Successful treatment of mast cell activation syndrome with sunitinib.

Afrin LB, Cichocki FM, Patel K, Molderings GJ.

Eur J Haematol. 2015 Dec;95(6):595-7. doi: 10.1111/ejh.12606. Epub 2015 Jun 25.

PMID:
26072665
15.

Mast Cell Activation Disease and Microbiotic Interactions.

Afrin LB, Khoruts A.

Clin Ther. 2015 May 1;37(5):941-53. doi: 10.1016/j.clinthera.2015.02.008. Epub 2015 Mar 12. Review.

PMID:
25773459
16.

Improving clinical trial accrual by streamlining the referral process.

Afrin LB, Oates JC, Kamen DL.

Int J Med Inform. 2015 Jan;84(1):15-23. doi: 10.1016/j.ijmedinf.2014.09.001. Epub 2014 Sep 16.

17.

Mast cell activation syndrome as a significant comorbidity in sickle cell disease.

Afrin LB.

Am J Med Sci. 2014 Dec;348(6):460-4. doi: 10.1097/MAJ.0000000000000325.

18.

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Costa LJ, Fanning SR, Stephenson J Jr, Afrin LB, Kistner-Griffin E, Bentz TA, Stuart RK.

Leuk Lymphoma. 2015 Mar;56(3):645-9. doi: 10.3109/10428194.2014.935369.

PMID:
25130476
19.

Improved metastatic uterine papillary serous cancer outcome with treatment of mast cell activation syndrome.

Afrin LB, Spruill LS, Schabel SI, Young-Pierce JL.

Oncology (Williston Park). 2014 Feb;28(2):129-31, 134. No abstract available.

20.

Utility of hydroxyurea in mast cell activation syndrome.

Afrin LB.

Exp Hematol Oncol. 2013 Oct 9;2(1):28. doi: 10.1186/2162-3619-2-28.

Supplemental Content

Loading ...
Support Center